Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
Li V, McKay FC, Tscharke DC, Smith C, Khanna R, Lechner-Scott J, Rawlinson WD, Lloyd AR, Taylor BV, Morahan JM, Steinman L, Giovannoni G, Bar-Or A, Levy M, Drosu N, Potter A, Caswell N, Smith L, Brady EC, Frost B, Hodgkinson S, Hardy TA, Broadley SA; Australian Anti-EBV Drugs for MS Working Group. Li V, et al. Among authors: hardy ta. CNS Drugs. 2025 Jan 10. doi: 10.1007/s40263-024-01153-5. Online ahead of print. CNS Drugs. 2025. PMID: 39792343
Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.
Campbell JA, Henson GJ, Ngwa VF, Ahmad H, Taylor BV, van der Mei I; MSBase Australian Researchers; Palmer AJ. Campbell JA, et al. Pharmacoeconomics. 2024 Dec 30. doi: 10.1007/s40273-024-01461-0. Online ahead of print. Pharmacoeconomics. 2024. PMID: 39739244 No abstract available.
Cerebrovascular damage caused by the gut microbe/host co-metabolite p-cresol sulfate is prevented by blockade of the EGF receptor.
Shah SN, Knausenberger TB, Pontifex MG, Connell E, Le Gall G, Hardy TAJ, Randall DW, McCafferty K, Yaqoob MM, Solito E, Müller M, Stachulski AV, Glen RC, Vauzour D, Hoyles L, McArthur S. Shah SN, et al. Among authors: hardy taj. Gut Microbes. 2024 Jan-Dec;16(1):2431651. doi: 10.1080/19490976.2024.2431651. Epub 2024 Nov 24. Gut Microbes. 2024. PMID: 39582109 Free PMC article.
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.
Campbell JA, Henson GJ, Ngwa VF, Ahmad H, Taylor BV, van der Mei I; MSBase Australian Researchers; Palmer AJ. Campbell JA, et al. Pharmacoeconomics. 2024 Aug 2. doi: 10.1007/s40273-024-01417-4. Online ahead of print. Pharmacoeconomics. 2024. PMID: 39095665
The clinical relevance of MOG antibody testing in cerebrospinal fluid.
Reynolds M, Tan I, Nguyen K, Merheb V, Lee FXZ, Trewin BP, Lerch M, Shah S, Wolfe N, Buzzard K, Lechner-Scott J, Fabis-Pedrini M, Fok A, John N, Kneebone C, Yiannikas C, Brown DA, Kermode AG, Reddel S, Dale RC, Brilot F, Ramanathan S; Australasian MOGAD Study Group. Reynolds M, et al. Ann Clin Transl Neurol. 2024 Sep;11(9):2514-2519. doi: 10.1002/acn3.52163. Epub 2024 Jul 28. Ann Clin Transl Neurol. 2024. PMID: 39073255 Free PMC article.
122 results